CAR-T Cell Therapy Market Size, Share and Forecast 2026
The CAR-T Cell Therapy market was valued at USD XX million in 2018 and expected to grow at a CAGR of XX% to reach a market value of USD XX million by 2026.
(EMAILWIRE.COM, September 13, 2019 ) Market Overview:
Chimeric antigen receptor T-cell therapy, also called CAR-T therapy, is the type of treatment in which a patient's T cells have been genetically engineered to produce chimeric antigen receptor (CAR) T-cells which are used to recognize cancer cells to more effectively target and destroy them. CARs are proteins that allow the T cells to recognize an antigen on specific tumor cells.
Market Dynamics:
The global market for the CAR-T Cell Therapy Market is primarily driven by the growing prevalence of cancer coupled with high demand for an effective treatment for cancer. However, the stringent regulations, side effects leading to neurological problems coupled with the high cost of treatment may hinder market progress.
Market Segmentation:
By Target Antigen
• CD 19
• CD 20
• GD2
• CD22
• CD30
• CD33
• HER1
• HER2
• Meso
• EGFRV III
• Others
By Therapeutic Application
• Acute Lymphoblastic Leukemia (ALL)
• Chronic lymphocytic leukemia (CLL)
• Non-Hodgkin lymphoma
• Acute myeloid leukemia (AML)
• Neuroblastoma
• Multiple myeloma (MM)
• Others
Geographical Analysis:
By Geography, the market is segmented into:
• North America
• Europe
• South America
• Asia Pacific
• The Middle East and Africa
Competitive Analysis:
Key players:
• Pfizer, Inc.
• Novartis AG
• Juno Therapeutics, Inc. (Celgene Corporation)
• Kite Pharma, Inc. (Gilead Sciences Inc.)
• bluebird bio (Celgene Corporation)
• Bellicum Pharmaceuticals, Inc.
• Others
View full report: hhttps://www.datamintelligence.com/research-report/car-t-cell-therapy-market
Download free sample: https://www.datamintelligence.com/download-sample/car-t-cell-therapy-market
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at Data M Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
Chimeric antigen receptor T-cell therapy, also called CAR-T therapy, is the type of treatment in which a patient's T cells have been genetically engineered to produce chimeric antigen receptor (CAR) T-cells which are used to recognize cancer cells to more effectively target and destroy them. CARs are proteins that allow the T cells to recognize an antigen on specific tumor cells.
Market Dynamics:
The global market for the CAR-T Cell Therapy Market is primarily driven by the growing prevalence of cancer coupled with high demand for an effective treatment for cancer. However, the stringent regulations, side effects leading to neurological problems coupled with the high cost of treatment may hinder market progress.
Market Segmentation:
By Target Antigen
• CD 19
• CD 20
• GD2
• CD22
• CD30
• CD33
• HER1
• HER2
• Meso
• EGFRV III
• Others
By Therapeutic Application
• Acute Lymphoblastic Leukemia (ALL)
• Chronic lymphocytic leukemia (CLL)
• Non-Hodgkin lymphoma
• Acute myeloid leukemia (AML)
• Neuroblastoma
• Multiple myeloma (MM)
• Others
Geographical Analysis:
By Geography, the market is segmented into:
• North America
• Europe
• South America
• Asia Pacific
• The Middle East and Africa
Competitive Analysis:
Key players:
• Pfizer, Inc.
• Novartis AG
• Juno Therapeutics, Inc. (Celgene Corporation)
• Kite Pharma, Inc. (Gilead Sciences Inc.)
• bluebird bio (Celgene Corporation)
• Bellicum Pharmaceuticals, Inc.
• Others
View full report: hhttps://www.datamintelligence.com/research-report/car-t-cell-therapy-market
Download free sample: https://www.datamintelligence.com/download-sample/car-t-cell-therapy-market
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at Data M Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
Contact Information:
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results